Theramir Limited is a pioneering biotechnology company specializing in the development of innovative microRNA-based therapeutics and companion diagnostics aimed at treating cancer. Operating in the healthcare and biotechnology sectors, Theramir focuses on creating novel solutions that leverage microRNAs, a class of small non-coding RNAs capable of regulating multiple genes and pathways associated with cancer growth and metastasis. The company's proprietary technologies include both biological and synthetic microRNAs designed to disrupt the expression of oncoproteins that are dysregulated in various cancer types.

Theramir serves a diverse range of clients, including patients, healthcare providers, and research institutions. The company operates on a B2B and B2C business model, generating revenue through the development and sale of targeted therapeutics and diagnostic tools. Additionally, Theramir collaborates with pharmaceutical companies and research organizations to further enhance its product offerings and expand its market reach.

Key features of Theramir's offerings include targeted delivery strategies, companion diagnostic tools, and PDX (Patient-Derived Xenograft) studies, which provide a comprehensive approach to cancer treatment and diagnosis. By focusing on precision medicine, Theramir aims to improve patient outcomes and advance the field of oncology.

Keywords: microRNA, cancer therapeutics, diagnostics, targeted treatment, precision medicine, biotechnology, oncoproteins, healthcare, PDX studies, non-coding RNAs.